Trial Profile
A Randomized Open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-chain (AL) Amyloidosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Melphalan
- Indications Amyloidosis
- Focus Therapeutic Use
- Acronyms ALLG MM13; EMN-03
- 06 Dec 2016 Primary endpoint has been met. (Overall hematologic response at 3 months) as per results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 10 Aug 2016 Status changed from recruiting to completed.